Tango Therapeutics (TNGX) drew fresh attention after launching a Phase 1/2 trial combining vopimetostat with ERAS-0015 for MTAP-deleted pancreatic and lung cancers, alongside increased visibility from a large institutional holder.
Against that backdrop, Tango Therapeutics has seen strong momentum build, with a 7 day share price return of 18.60% and a year to date share price gain of 185.55%. The 1 year total shareholder return of 212.12% and 3 year total shareholder return of 235.53% point to investors rewarding the story despite recent quarterly losses and trial related volatility.
Scan beyond Tango Therapeutics and explore other high momentum biotech stories using the curated 19 high quality undiscovered gems, which highlights companies that share strong fundamentals but remain under the radar.
Tango Therapeutics now trades with a very strong recent run and deep clinical losses on the table. Does that balance still offer an appealing entry once you put a valuation lens over it?
The analyst consensus Narrative on Simply Wall St marks fair value for Tango Therapeutics at $47.09 versus a last close of $25.50. This frames a wide gap that hinges on ambitious cancer trial goals and long dated earnings assumptions.
The main thing that has to go right is for vopimetostat based regimens, including RAS inhibitor combinations, to convert strong response and PFS data into successful late-stage trials in competitive indications like pancreatic cancer.
The current valuation, including a stock price that has risen around 7 to 8 times over the past year alongside multiple Buy or Overweight ratings and higher price targets, implies that the market is pricing in meaningful commercial potential for the vopimetostat franchise.
See why 2 investors see Tango Therapeutics as 46% undervalued.
Result: Fair Value of $47.09 (UNDERVALUED)
Still, the narrative around Tango Therapeutics leans heavily on vopimetostat delivering in difficult pancreatic cancer trials and on equity funded plans that could amplify volatility if data disappoints.
Find out about the key risks to this Tango Therapeutics narrative.
This mix of enthusiasm and caution around Tango Therapeutics only matters if you test it against your own expectations and risk tolerance. Take a few minutes to weigh both sides by checking the 1 key reward and 4 important warning signs.
If Tango Therapeutics has your attention, do not stop here. The next strong idea often comes from comparing a few different setups side by side.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com